Evaluation of white blood cell- and platelet-derived cytokine accumulation in MIRASOL-PRT-treated platelets

Transfusion Medicine and Hemotherapy

Volumn 36, Issue 2, 2009, Pages 114-120

  Picker, Susanne M ^a   Steisel, Alexander ^a   Gathof, Birgit S ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Ccytokines; Mirasol PRT; Pathogen reduction; Transfusion reaction

Indexed keywords

CXCL4 CHEMOKINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; LACTATE DEHYDROGENASE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; RANTES; THROMBOCYTE CONCENTRATE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

APHERESIS; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GAMMA IRRADIATION; HUMAN; LEUKOCYTE; LEUKOCYTE TRANSFUSION; PATHOGEN REDUCTION TECHNOLOGY; TECHNOLOGY; TH1 CELL; TH2 CELL; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTE PRESERVATION; THROMBOCYTE TRANSFUSION;

EID: 65349173082     PISSN: 16603796     EISSN: None     Source Type: Journal    
DOI: 10.1159/000203359     Document Type: Article

References (38)

1. Heddle NM, Klama L, Meyer R, Walker I, Boshkov L, Roberts R, Chambers S, Podlosky L, O'Hosky P, Levine M: A randomized controlled trial comparing plasma removal with white cell reduction to prevent reactions to platelets. Transfusion 1999;39:231-238.
2. Heddle NM, Klama I, Singer J, Richards C, Fedak P, Walker I, Kelton JG: The role of the plasma from platelet concentrates in transfusion reactions. N Eng J Med 1994;331:625-628.
3. Klüter H, Bubel S, Kirchner H, Wilhelm D: Febrile and allergic transfusion reactions after the transfusion of white cell-poor platelet preparations. Transfusion 1999;39:1179-1184.
4. Spiess BD, Royston D, Levy JH, Fitch J, Dietrich W, Body S, Murkin J, Nadel A: Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes. Transfusion 2004;44:1143-1148.
5. Lösche W, Heptinstall S: Value of platelet activation markers as prothrombotic risk indicators. Transfus med Hemother 2007;34:34-42.
6. Paglino JC, Pomper GJ, Fisch GS, Champion MH, Snyder EL: Reduction of febrile but not allergic reactions to RBCs and platelets after conversion to universal prestorage leukoreduction. Transfusion 2004;44:16-24.
7. Yazer MH, Podlosky L, Clarke G, Nahirniak SM: The effect of prestorage WBC reduction on the rates of febrile nonhemolytic transfusion reactions to platelet concentrates and RBC. Transfusion 2004;44:10-15.
8. Heddle NM, Blajchman MA, Meyer RM, Lipton JH, Walker IR, Sher GD, Constantini LA, Patterson B, Roberts RS, Thorpe KE, Levine MN: A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets. Transfusion 2002;42:556-566.
9. Wakamoto S, Fujihara M, Kuzuma K, Sato S, Kato T, Naohara T, Kasai M, Sawada K, Kobayashi R, Kudoh T, Ikebuchi K, Azuma H, Ikeda H: Biologic activity of RANTES in apheresis PLT concentrates and its involvement in nonhemolytic transfusion reactions. Transfusion 2003;43:1038- 1046.
10. Alam R, Stafford S, Forsythe P, Harrison R, Faubion D, Lett-Brown MA, Grant JA: RANTES is a chemotactic and activating factor for human eosinophils. J Immunol 1993;150:3442-3448.
11. Rot A, Krieger M, Brunner T, Bischoff SC, Schall TJ, Dahinden CA: RANTES and macrophage inflammatory protein 1 alpha induce the migration and activation of normal human eosinophil granulocytes. J Exp Med 1992;176:1489-1495.
12. Kuna P, Reddigari SR, Schall TJ, Rucinski D, Viksman MY, Kaplan AP: RANTES, a monocyte and T lymphocyte chemotactic cytokine releases histamine from human basophils. J Immunol 1992; 149:636-642.
13. Apelseth TO, Hervig TA, Wetzel-Larsen T, Bruserud Ø: Cytokine accumulation in photochemically treated and gamma-irradiated platelet concentrates during storage. Transfusion 2006;46: 800-810.
14. Hei DJ, Grass J, Lin L, Corash L, Cimino G: Elimination of cytokine production in stored platelet concentrate aliquots by photochemical treatment with psoralen plus ultraviolet A light. Transfusion 1999;39:239-248.
15. Fast LD, DiLeone G, Li J, Goodrich R: Functional inactivation of white blood cells by Mirasol treatment. Transfusion 2006;4446:642-648.
16. Sottile J, Mosher DF, Fullenweider J, George JN: Human platelets contain mRNA transcripts for platelet factor 4 and actin. Thromb Haemost 1989;62:1100-1102.
17. Bruce IJ, Kerry R: The effect of chloramphenicol and cycloheximide on platelet aggregation and synthesis. Biochem Pharmacol 1987;36:1769-1773.
18. Caspari G, Gerlich WH, Kiefel V, Gürtler L: Pathogen inactivation of cellular blood products - still plenty of reason to be careful. Transfus Med Hemother 2005;32:258-260.
19. German Medical Association and Paul-Ehrlich- Institute: Guidelines for the Collection of Blood and Blood Components and the Usage of Blood Products (Hemotherapy), rev. ed. Cologne, Deutscher Ärzteverlag, 2005.
20. Council of Europe: Guide to the Preparation, Use and Quality Assurance of Blood Components. 13th ed. Strassbourg, France, Council of Europe Publishing, 2007.
21. Li J, Lockerbie O, De Korte D, Rice J, McLean R, Goodrich RP: Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology. Transfusion 2005;45:920-926.
22. Perez-Pujol S, Tonda R, Lozano M, Fuste B, Lopez-Vilchez I, Galan AM, Li J, Goodrich R, Escolar G: Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion 2005;45:911- 919.
23. Goodrich RP, Li J, Pieters H, Crookes R, Roodt J, Heyns AP: Correlation of in vitro platelet quality measurements with in vivo platelet viability in human subjects. Vox Sang 2006;90:279-285.
24. Li J, De Korte D, Woolum MD, Ruane PH, Keil SD, Lockerbie O, McLean R, Goodrich RP: Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products. Vox Sang 2004;87:82-90.
25. Picker SM, Speer R, Gathof BS: Functional characteristics of buffy-coat PLTs photochemically treated with amotosalen-HCl for pathogen inactivation. Transfusion 2004;44:320-329.
26. Gear AR, Camerini D: Platelet chemokines and chemokine receptors: linking hemostasis, inflammation, and host defense. Microcirculation 2003; 10:335-350.
27. Lindemann S, Tolley ND, Dixon DA, McIntyre TM, Prescott SM, Zimmerman GA, Weyrich AS: Activated platelets mediate signaling by regulated interleukin 1 beta synthesis. J Cell Biol 2001;154: 485-490.
28. Hartwig D, Härtel C, Hennig H, Müller-Steinhardt M, Schlenke P, Klüter H: Evidence for de novo synthesis of cytokines and chemokines in platelet concentrates. Vox Sang 2002;82:182-190.
29. Cazenave JP, Aleil B, Wiesel ML, Laforêt M, Isola H: In vitro evaluation of pooled buffy coat platelets treated with photochemical pathogen inactivation using amotosalen. Vox Sang 2004;86:201- 202.
30. Wadhwa M, Krailadsiri P, Dilger P, Gaines Das R, Seghatchian MJ, Thorpe R: Cytokine levels as performance indicators for white blood cell reduction of platelet concentrates. Vox Sang 2002;83: 125-136.
31. Cardigan R, Sutherland J, Wadhwa M, Dilger P, Thorpe R: The influence of platelet additive solutions on cytokine levels and complement activation in platelet concentrates during storage. Vox Sang 2003;84:28-35.
32. Böck M, Rahrig S, Kunz D, Lutze G, Heim MU: Platelet concentrates derived from buffy coat and apheresis: biochemical and functional differences. Transfus Med 2002;12:317-324.
33. Fujihara M, Ikebuchi K, Wakamoto S, Sekiguchi S: Effects of filtration and gamma radiation on the accumulation of RANTES and transforming growth factor beta 1 in apheresis platelet concentrates during storage. Transfusion 1999;39:498- 505.
34. Turner CP, Sutherland J, Wadhwa M, Dilger P, Cardigan R: In vitro function of platelet concentrates prepared after filtration of whole blood or buffy coat pools. Vox Sang 2005;88:164-171.
35. Shanwell A, Falker C, Gulliksson H: Storage of platelets in additive solutions. The effects of magnesium and potassium on the release of RANTES, beta-thromboglobulin, platelet factor 4 and interleukin- 7, during storage. Vox Sang 2003;85:206- 212.
36. de Wildt-Eggen J, Schrijver JG, Smid WM, Joie M, Bollinne V, Bins M: Platelets stored in a new generation container. Differences between plasma and platelet additive solution II. Vox Sang 1998;75:218-223.
37. Van Rhenen D, Gulliksson H, Cazenave JP, Pamphilon D, Ljungman P, Klüter H, Vermeij H, Kappers- Klunne M, de Greef G, Laforet M, Lioure B, Davis K, Marblie S, Mayaudon V, Flament J, Conlan M, Lin L, Metzel P, Buchholz D, Corash L: Transfusion of pooled buffy-coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003;101:2426-2433.
38. Mc Cullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, Stadtmauer EA, Lopez- Plaza I, Coutre S, Strauss RG, Goodnough LT, Fridey JL, Raife T, Cable R, Murphy S, Howard F 4th, Davis K, Lin JS, Metzel P, Corash L, Koutsoukos A, Lin L, Buchholz DJ, Conlan MG: Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004;104:1534-1541.